Next-Generation Point-of-Care Solution
A Lab In Your Hand
Proxim has developed a next-generation handheld immunodiagnostic device. The system performs the most important laboratory tests near the patient using whole blood without any sacrifice in sensitivity and precision, bringing the most critical information to the doctors right when they need it. The instrument is battery operated, has touch-screen display interface, wireless, Ethernet, and USB connectivity.
Point-of-Care vs. Central Lab
Special attention was given to the disposable test cartridge, which can be manufactured at a low cost. Proxim’s unique combination of high performance and low cost not only make it ideal for hospital emergency departments in the USA but also in other settings around the world.
According to CDC, every year at least 1.7 millions American adults develop sepsis and early 270,000 dies. For each hour sepsis treatment is delayed, the patient's risk of death increases by 4 percent, making our point-of-care solution especially valuable. PCT allows differentiation of patients where sepsis is caused by bacterial infection.
Measurement range: 0.01 ng/ml .. 30 ng/ml
Fischer et al, "Development of an IL-6 point-of-care assay: utility for real-time monitoring and management of cytokine release syndrome and sepsis", Bioanalysis, (2019).
Wacker et al, "Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis", The Lancet, (2013).
Del Valle et al, "An inflammatory cytokine signature predicts COVID-19 severity and survival", Nature Medicine, (2020).
Apple and Collinson, "Analytical characteristics of high-sensitivity cardiac troponin assays", Clinical Chemistry, (2012).
Proxim internal studies with whole blood using multiple instruments and cartridge lots.
Weber and Hamm, "Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine", Heart, (2006).
Wells et al, "Evaluation of D-Dimer in the diagnosis of suspected deep-vein thrombosis", New England J. of Medicine, (2003).
Young et al, "Clinical evaluation of BD Veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS Antigen point-of-care test", Virology, (2020).
CEO, Co-Founder, Board Director
PhD in Physics, UCLA
Constantly inventing and developing sensor technologies. Driven to transform technology into products that can be made inexpensively and that people will want to use.
Co-Founder, Board Director
MBA, Wharton & MS, Stanford
Passion for advanced materials and their applications. Goal is to get better and cheaper treatments into the hands of healthcare providers around the globe.
MBA, University of Chicago
Angel investor in healthcare companies. Senior customer relationships executive with extensive knowledge of complex telco solutions and working with global clients.
CFP, ChFC, BA in Finance, University of Wisconsin
Angel investor and board member of multiple startup companies. President & CEO of BrightStar Wisconsin Foundation, ex-CEO of Prodesse (sold to Gen-Probe).